136 related articles for article (PubMed ID: 29742075)
21. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer imaging.
Kundra V
Semin Roentgenol; 2006 Apr; 41(2):139-49. PubMed ID: 16697892
[No Abstract] [Full Text] [Related]
23. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
Mottaghy FM; Heinzel A; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
[No Abstract] [Full Text] [Related]
24. [3. Diagnostic Imaging for Prostate Cancer].
Yoshida R; Yoshizako T; Kitagaki H
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2017; 73(6):477-485. PubMed ID: 28637962
[No Abstract] [Full Text] [Related]
25. Molecular Imaging of Recurrent and Metastatic Prostate Cancer.
Ware RE; Williams S; Hicks RJ
Semin Nucl Med; 2019 Jul; 49(4):280-293. PubMed ID: 31227051
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
27. The expanding landscape of diffusion-weighted MRI in prostate cancer.
Wibmer AG; Sala E; Hricak H; Vargas HA
Abdom Radiol (NY); 2016 May; 41(5):854-61. PubMed ID: 26814501
[TBL] [Abstract][Full Text] [Related]
28. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
Shakespeare TP
Radiat Oncol; 2015 Nov; 10():233. PubMed ID: 26582424
[TBL] [Abstract][Full Text] [Related]
29. How does endorectal MRI, PET-CT and transrectal ultrasound contribute to diagnosis and management of localized prostate cancer.
Rincón Mayans A; Diaz-Tejeiro BZ; Rioja Zuazu J; Díaz Dorronsoro L; Rodriguez Fraile M; Boillos AB; Bergera JZ
Arch Esp Urol; 2011 Oct; 64(8):746-64. PubMed ID: 22052757
[TBL] [Abstract][Full Text] [Related]
30. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
31. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
[TBL] [Abstract][Full Text] [Related]
32. Molecular Imaging of Prostate Cancer.
Wibmer AG; Burger IA; Sala E; Hricak H; Weber WA; Vargas HA
Radiographics; 2016; 36(1):142-59. PubMed ID: 26587888
[TBL] [Abstract][Full Text] [Related]
33. Impact of functional imaging in prostate cancer: a clinical point of view.
Nicolotti DG; Finessi M; Guarneri A; Pilati E; Giunta F; Deandreis D
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):1-6. PubMed ID: 30644307
[No Abstract] [Full Text] [Related]
34. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
35. Is There Use for FDG-PET in Prostate Cancer?
Jadvar H
Semin Nucl Med; 2016 Nov; 46(6):502-506. PubMed ID: 27825430
[TBL] [Abstract][Full Text] [Related]
36. Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology.
Jadvar H
J Nucl Med; 2018 Sep; 59(9):1338-1339. PubMed ID: 30030344
[No Abstract] [Full Text] [Related]
37. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
Jadvar H
J Nucl Med; 2016 Oct; 57(Suppl 3):25S-29S. PubMed ID: 27694167
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Prostate Cancer with 11C-Acetate PET/CT.
Spick C; Herrmann K; Czernin J
J Nucl Med; 2016 Oct; 57(Suppl 3):30S-37S. PubMed ID: 27694168
[TBL] [Abstract][Full Text] [Related]
39. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
40. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
